{
    "clinical_study": {
        "@rank": "157951", 
        "arm_group": [
            {
                "arm_group_label": "Henna-propolis arm", 
                "arm_group_type": "Experimental", 
                "description": "Based on the treatment protocol for this study the patients  will receive the henna and propolis treatment for 12 weeks (supervised treatment for first week and then unsupervised sessions twice a week). The treatment will include the application of the henna mixture (paste) (40gr natural henna and 40ml of purified water) to the affected areas (feet or/and hands) and wear socks or/and gloves. The treatment session will last for 2 hours and then the mixture will be rinsed with fresh water and the propolis (olive oil based) applied."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Based on the treatment protocol for this study the patients in this arm will receive the henna and propolis placebo treatment for 12 weeks (supervised treatment for first week and then unsupervised sessions twice a week). The treatment will include the application of the henna mixture (paste) (40gr natural henna and 40ml of purified water) to the affected areas (feet or/and hands) and wear socks or/and gloves. The treatment session will last for 2 hours and then the mixture will be rinsed with fresh water and the propolis (olive oil based) placebo applied."
            }
        ], 
        "brief_summary": {
            "textblock": "The palmar-plantar erythrodysesthesia (PPE) is the only clinical adverse event that commonly\n      occurs with capecitabine and/or pegylated liposomal doxorubicin treatment and it warrants\n      special attention because it is the most common dose-limiting toxicity. this study is\n      designed to test the effectiveness of a henna and propolis treatment protocol in the\n      management of capecitabine and/or pegylated liposomal doxorubicin induced palmar-plantar\n      erythrodysesthesia."
        }, 
        "brief_title": "The Use of Henna and Propolis on PPE", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Palmar-plantar Erythrodysesthesia (PPE)", 
        "detailed_description": {
            "textblock": "This will be a randomized double-blind, placebo-controlled study with 250 cancer patients\n      that will receive chemotherapy treatment with capecitabine and/or pegylated liposomal\n      doxorubicin. The selection of potential participants will be based on pre-determined\n      inclusion and exclusion criteria. Patients will be randomly allocated either to the\n      treatment group or the placebo group. Treatment will be delivered twice a week and\n      assessments will take place at 0, 4, 8 and 12 weeks. The intervention group will receive the\n      application of henna and propolis to the hands and/or feet of the patients and the control\n      group will receive the placebo. At both baseline and follow-up, patients in both groups will\n      be assessed for their degree of palmar-plantar erythrodysesthesia, the Quality of Life, the\n      need for dose-limiting due to PPE and Pain intensity using standardized rating scales. Data\n      will be analysed with inferential and descriptive statistics."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult cancer patients (>18)\n\n          -  Patients receiving capecitabine and/or PLD as monotherapy or in combination with\n             other agents\n\n          -  Patients that will experience PPE grade 1 or above\n\n          -  Willing to participate\n\n          -  Ability to complete the psychometric assessments.\n\n          -  A performance status of two or less on the Eastern Cooperative Oncology Group (ECOG)\n\n        Exclusion Criteria:\n\n          -  Patients with hypersensitivity to natural henna or/and honey or/and olive oil.\n\n          -  Patients with pre-existing dermatological condition affecting the hands or feet that\n             may limit the interpretation of results\n\n          -  Patients on Pyridoxine or nicotine patches\n\n          -  Patients with a previous history of PPE\n\n          -  Patients whose chemotherapy was discontinued for more than a week"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01751893", 
            "org_study_id": "AC-PPEHP-88"
        }, 
        "intervention": [
            {
                "arm_group_label": "Henna-propolis arm", 
                "intervention_name": "Henna-Propolis", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Doxorubicin", 
                "Capecitabine", 
                "Lawsone", 
                "Propolis"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hand-foot syndrome", 
            "palmar-plantar erythrodysesthesia", 
            "capecitabine", 
            "pegylated liposomal doxorubicin", 
            "henna", 
            "propolis"
        ], 
        "lastchanged_date": "December 20, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nicosia", 
                    "country": "Cyprus", 
                    "zip": "2006"
                }, 
                "name": "Bank of Cyprus Oncology"
            }, 
            "investigator": {
                "last_name": "Michalis Stavrinou, BSc", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Cyprus"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Double-blind, Placebo-controlled Study of the Effects of a Combination of Propolis and Lawsonia Inermis on Palmar-Plantar Erythrodysesthesia Induced by Capecitabine and/or Pegylated Liposomal Doxorubicin", 
        "other_outcome": [
            {
                "description": "The ability of the patients to respond to their activities of daily living will be assessed with the Eastern Co-operative Oncology Group (ECOG)/WHO system", 
                "measure": "Activities of daily living", 
                "safety_issue": "No", 
                "time_frame": "3,4,5 weeks"
            }, 
            {
                "description": "The patients will report any possible side-effect due to the treatment (i.e rash)", 
                "measure": "Treatment side-effects", 
                "safety_issue": "Yes", 
                "time_frame": "3,4,5 weeks"
            }
        ], 
        "overall_contact": {
            "email": "andreas.charalambous@cut.ac.cy", 
            "last_name": "Andreas Charalambous, PhD", 
            "phone": "+357252011"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Cyprus: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The grade of PPE will be assessed with a standardised three-grade system previously used in capecitabine clinical trials", 
            "measure": "PPE grade", 
            "safety_issue": "No", 
            "time_frame": "up to 3 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01751893"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Cyprus University of Technology", 
            "investigator_full_name": "Dr. Andreas Charalambous", 
            "investigator_title": "Lecturer of Oncology and Palliative Care", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The quality of life of the patients will be assessed with the EORTC QOLc30 module which has been developed and validated explicitly for patients suffering from cancer.", 
                "measure": "EORTC QOLc30", 
                "safety_issue": "No", 
                "time_frame": "3,4,5 weeks"
            }, 
            {
                "description": "this is a quality of life scale for patients experiencing radiation-induced PPE", 
                "measure": "Hand-foot syndrome 14 (HFS-14)", 
                "safety_issue": "No", 
                "time_frame": "3,4,5 weeks"
            }
        ], 
        "source": "Cyprus University of Technology", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cyprus University of Technology", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}